iwAL MRD working group session
Chairs: Naval Daver & Andrew Wei

 

Part 1: Prognostic implications

• Flow cytometry: Sanam Loghavi
• NPM1: Jad Othman
• FLT3: Christopher Hourigan
• Should we intervene at MRD persistence or recurrence?: Farhad Ravandi

 

Part 2: Endpoints for clinical trials: Michael Heuser

 

Part 3: MRD-directed therapies

• Talk title TBC: Andrew Wei
• Talk title TBC: Naval Daver

 

Part 4: FDA perspective

• FDA clinical perspective: TBC
• FDA statistical perspective: TBC
• FDA devices perspective: TBC

 

Part 5: Panel discussion

Welcome & introduction
Naval Daver

Session 1: Translational and lab developments and applications in AML
Chairs: Ravindra Majeti & Iannis Aifantis

• Clonal evolution of therapy-related myeloid neoplasms: Koichi Takahashi
• RAS pathway activation drives resistance to gilteritinib and venetoclax: Catherine Smith
• Understanding myeloid neoplasms in patients after CAR-T therapy: Ann-Kathrin Eisfeld

Panel discussion

Session 2: New science implications for AML
Chairs: Koichi Takahashi & Paresh Vyas

• Stem cells in human AML: Ravindra Majeti
• Transcriptomic and geographical mapping of extramedullary AML: Iannis Aifantis
• The aging of the blood system and diagnosis of leukemia from the peripheral blood: Liran Shlush

Panel discussion

Session 3: Transplantation in AML
Chairs: Paresh Vyas & Eytan Stein

• GVL new approaches: Paresh Vyas
• Strategies to optimise transplant outcomes: Charles Craddock
• Debate: Is pre-transplant intervention warranted in patients with MRD+ AML CR1?
  • Yes: Maximilian Stahl
  • No: Roland Walter

Panel discussion

Day 1 conclusions
Naval Daver

Welcome to Day 2
Naval Daver

Session 4: Updates on established therapies in AML
Chairs: Jessica Altman & Andrew Wei

• Intensive or non-intensive induction: Curtis Lachowiez
• Optimal approach to treatment of secondary/therapy-related AML: Tara Lin
• Improving induction strategies: Tapan Kadia
• Venetoclax de-escalation: Stéphane de Botton

Panel discussion

Session 5: Immunotherapies in AML
Chairs: Marion Subklewe & Roland Walter

• Early-phase CAR and γδ T cell immunotherapy trials for R/R AML and MDS: Nelli Bejanyan
• NK cell-based therapies in AML: Jeffrey Miller
• TCEs & CAR-T in AML: Let’s try that again: Marion Subklewe
• Mitigating CRS during immunotherapy for AML: John DiPersio

Panel discussion

Break

Session 6: Targeting FLT3-mutant AML
Chairs: Richard Stone & Amir Fathi

• Frontline approaches for FLT3-mutant AML: Naval Daver
• Current approaches and challenges for relapsed FLT3-mutant AML: Jessica Altman
• Mechanisms of resistance to FLT3 inhibitors and how we can overcome them: Alexander Perl
• Designing and applying a FLT3-like signature in AML: Adrián Mosquera Orgueira

Panel discussion

Session 7: International trials group
Chairs: Naval Daver & Charles Craddock

• UK trials: Charles Craddock
• US trials: Harry Erba
• French trials: TBC

Panel discussion

Lunch

Session 8: Value and utility of MRD in the management of adults with newly-diagnosed AML
Chairs: Mark Levis & Farhad Ravandi

• Debate: MRD technology is an expensive luxury in the management of the majority of fit adults with newly-diagnosed AML
  • For: Harry Erba & Eunice Wang
  • Against: Sanam Loghavi & Roland Walters

Panel discussion

Keynote talk 1
Talk title TBC: Gail Roboz

 

Break

Session 9: New frontiers in MRD for AML: Regulatory perspective and clinical practice
Chairs: Naval Daver, Gail Roboz & TBC

• Cell-free DNA determinants of AML MRD: Tian Yi Zhang
• MRD as a clinical endpoint in clinical trials: Christopher Hourigan
• Talk title TBC: TBC

Panel discussion

Session 10: Clonal hematopoiesis, BPDCN & CMML
Chairs: Naveen Pemmaraju & Andrew Lane

• Potential for early intervention in CHIP and CCUS: Updates and ongoing trials: Uma Borate
• Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Targeting CD123: Naveen Pemmaraju
• PI3 kinase gamma: A novel target across AML, BPDCN, and CMML: Andrew Lane
• Future targets and trials progress in CMML: Guillermo Montalbán Bravo

Panel discussion

Day 2 conclusions
Charles Craddock

 

Welcome to Day 3

Keynote talk 2
Talk title TBC: Charles Craddock

Session 11: Menin inhibition in AML
Chairs: Naval Daver & Andrew Wei

• Single-agent menin inhibitors – efficacy, biomarkers and resistance: Ghayas Issa
• Menin inhibitor combinations: Joshua Zeidner
• Venetoclax or menin inhibitors for NPM1-mutated AML: Eytan Stein
• Mechanisms of resistance to menin inhibitors: Amir Fathi

Panel discussion

Session 12: TP53-mutated AML
Chairs: David Sallman & Eunice Wang

• Biological insights: Andrew Wei
• Management in 2025: Justin Watts
• Future strategies for TP53-mutated AML: How do we improve outcomes?: David Sallman
• Talk title TBC: Gabriel Mannis

Panel discussion

Break

Session 13: Novel targets, combinations and treatments in AML (part 1)
Chairs: Tapan Kadia & Gail Roboz

• IC+VEN in newly diagnosed fit AML – Who are the optimal patients for this approach?: Courtney DiNardo
• Optimal use of OGM and RNA translocation panel in frontline AML: Sanam Loghavi
• Overcoming resistance to venetoclax-based therapies in AML: Harry Erba

Panel discussion

Session 14: Novel targets, combinations and treatments in AML (part 2)
Chairs: Harry Erba & Ghayas Issa

• Promising combination options with AZA/VEN for R/R AML: Thomas Cluzeau
• Emerging combination strategies in AML: Hima Atluri
• Targeting the root: Novel approaches against leukemic stem cells in AML: Aditi Shastri

Panel discussion

Meeting summary and close
Naval Daver